Abbott revealed new data showing a significant rise in diabetic ketoacidosis (DKA) hospitalizations across all age groups in the U.S., especially among children with Type 1 diabetes. DKA, a dangerous condition caused by high ketone levels due to insufficient insulin, is often hard to detect early because symptoms mimic common illnesses and ketone monitoring is not routine. Abbott introduced a dual glucose-ketone sensor system, Libre Duo, approved in Europe and pending FDA clearance in the U.S., aiming to help patients detect rising ketones earlier and reduce costly hospital stays. This innovation addresses a critical gap in diabetes care by combining continuous glucose and ketone monitoring in one device.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
